Connect Biopharma Holdings Limited
Science and Technology Park
East R&D Building, 3rd Floor
6 Beijing West Road, Taicang
Jiangsu Province, China 215400
July 1, 2022
VIA EDGAR
Ms. Jane Park
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Connect Biopharma Holdings Limited |
Registration Statement on Form F-3
File No. 333-264340
Dear Ms. Park:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited (the “Company”), respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on July 6, 2022, or as soon as practicable thereafter.
Please contact Michael E. Sullivan of Latham & Watkins LLP, counsel to the Company, at (858) 523-3959, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
| Very truly yours, | ||
| CONNECT BIOPHARMA HOLDINGS LIMITED | ||
| By: | /s/ Zheng Wei, Ph.D. | |
| Zheng Wei, Ph.D. | ||
| Chief Executive Officer | ||
| cc: Jason | Drory, Securities Exchange Commission |
Jiang Bian, Esq., Connect Biopharma Holdings Limited
Michael E. Sullivan, Latham & Watkins LLP
Cheung Ying (Cathy) Yeung, Esq., Latham & Watkins LLP
Alan F. Denenberg, Davis Polk & Wardwell LLP
Emily Roberts, Davis Polk & Wardwell LLP
Donald K. Lang, Davis Polk & Wardwell LLP